Podcasts about National Health Service

Dr. Sarah Myhill has worked full time in National Health Service and independent medical practice. She has a special interest in CFS and ME. Show partners:  LMNT - Claim your free LMNT Sample Pack with any purchase by using this link Ketone-IQ - Save 30% off your subscription order plus youʼll get a free gift with your second shipment by using this link Troscriptions - 10% off your first order by using the code "JESSE" at checkout Quicksilver Scientific - 15% off your first order by using the code "jesse15" at checkout Show notes: https://jessechappus.com/688

Send Vikki any questions you'd like answered on the show!A critical inner voice is one of the most common and difficult experience as a PhD student or academic. In this episode, you get to hear me coaching TWO of my current students in the PhD Life Coach membership, who are both part time PhD students while holding down demanding careers in our National Health Service. It runs like one of our group coaching sessions, where they each get coached AND hear each other get coached on self-talk, prioritisation, and compassion. If you have a critical inner voice, or if you've ever wondered about the benefits of group coaching, then you're in the right place!If you liked this episode, you should check out my episode on How Winnie the Pooh can help you manage your mind.****I'm Dr Vikki Wright, ex-Professor and certified life coach and I help everyone from PhD students to full Professors to get a bit less overwhelmed and thrive in academia. Please make sure you subscribe, and I would love it if you could find time to rate, review and tell your friends! You can send them this universal link that will work whatever the podcast app they use. http://pod.link/1650551306?i=1000695434464 I also host a free online community for academics at every level. You can sign up on my website, The PhD Life Coach. com - you'll receive regular emails with helpful tips and access to free online group coaching every single month! Come join and get the support you need.

In this episode, we tackle the contentious issue of socialized medicine in America, with a spotlight on the failures of the National Health Service in Great Britain. John Solomon welcomes former British Prime Minister Liz Truss, who shares her firsthand experiences and insights into the pitfalls of government-run healthcare. We also discuss the implications of free speech in today's political climate with author Stuart Brotman. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this special end-of-year episode of Behind the Genes, host Sharon Jones is joined by Dr Rich Scott, Chief Executive Officer of Genomics England, to reflect on the past year at Genomics England, and to look ahead to what the future holds.  Together, they revisit standout conversations from across the year, exploring how genomics is increasingly embedded in national health strategy, from the NHS 10-Year Health Plan to the government's ambitions for the UK life sciences sector. Rich reflects on the real-world impact of research, including thousands of diagnoses returned to the NHS, progress in cancer and rare condition research, and the growing momentum of the Generation Study, which is exploring whether whole genome sequencing could be offered routinely at birth.  This episode offers a thoughtful reflection on how partnership, innovation, and public trust are shaping the future of genomic healthcare in the UK and why the years ahead promise to be even more exciting.  Below are the links to the podcasts mentioned in this episode, in order of appearance:  How are families and hospitals bringing the Generation Study to life? How can cross-sector collaborations drive responsible use of AI for genomic innovation? How can we enable ethical and inclusive research to thrive? How can parental insights transform care for rare genetic conditions? How can we unlock the potential of large-scale health datasets? Can patient collaboration shape the future of therapies for rare conditions? https://www.genomicsengland.co.uk/podcasts/what-can-we-learn-from-the-generation-study “There is this view set out there where as many as half of all health interactions by 2035 could be informed by genomics or other similar advanced analytics, and we think that is a really ambitious challenge, but also a really exciting one.”  You can download the transcript, or read it below. Sharon: Hello, and welcome to Behind the Genes.   Rich: This is about improving health outcomes, but it's also part of a broader benefit to the country because the UK is recognised already as a great place from a genomics perspective. We think playing our role in that won't just bring the health benefits, it also will secure the country's position as the best place in the world to discover, prove, and where proven roll out benefit from genomic innovations and we think it's so exciting to be part of that team effort.  Sharon: I'm Sharon Jones, and today I'll be joined by Rich Scott, Chief Executive Officer at Genomics England for this end of year special. We'll be reflecting on some of the conversations from this year's episodes, and Rich will be sharing his insights and thoughts for the year ahead. If you enjoyed this episode, we'd love your support, so please subscribe, rate, and share on your favourite podcast app. So, let's get started.  Thanks for joining me today, Rich. How are you?  Rich: Great, it's really good to be here.   Sharon: It's been a really exciting year for Genomics England. Can you tell us a bit about what's going on?  Rich: Yeah, it's been a really busy year, and we'll dive into a few bits of the components we've been working on really hard. One really big theme for us is it's been really fantastic to see genomics at the heart of the government's thinking. As we'll hear later, genomics is at the centre of the new NHS 10-year health plan, and the government's life sciences sector plan is really ambitious in terms of thinking about how genomics could play a role in routine everyday support of healthcare for many people across the population in the future and it shows a real continued commitment to support the building of the right infrastructure, generating the right evidence to inform that, and to do that in dialogue with the public and patients, and it's great to see us as a key part of that.  It's also been a really great year as we've been getting on with the various programmes that we've got, so our continued support of the NHS and our work with researchers accessing the National Genomic Research Library. It's so wonderful to see the continued stream of diagnoses and actionable findings going back to the NHS. It's been a really exciting year in terms of research, publications. In cancer, some really exciting publications on, for example, breast cancer and clinical trials. Really good partnership work with some industry partners, really supporting their work. For me, one of the figures we are always really pleased to see go up with time is the number of diagnoses that we can return thanks to research that's ongoing in the research library, so now we've just passed 5,000 diagnostic discoveries having gone back to the NHS, it really helps explain for me how working both with clinical care and with research and linking them really comes to life and why it's so vital.   And then, with our programmes, it's been great to see the Generation Study making good progress. So, working with people across the country, more than 25,000 families now recruited to the study, and we're beginning to hear about their experiences, including some of the families who've received findings from the programme. It's really nice to see and hear from Freddie's family, who talked to the press a bit about the finding that they received. Freddie was at increased risk of a rare eye cancer, and really pleasingly, it was possible to detect that early through the screening that was put in place. Again, it really brings to life why we're doing this, to make a difference and improve health outcomes.  Sharon: That's an incredible 12 months. Diving into that Generation Study piece and for listeners who don't know what that is, it's a research study in partnership with the NHS that aims to sequence the genomes of 100,000 newborn babies. On an episode from earlier in the year, we had mum, Rachel Peck, join the conversation, whose baby Amber is enrolled on a study. Let's year from Rachel now.  Rachel: From the parents' point of view, I guess that's the hardest thing to consent for in terms of you having to make a decision on behalf of your unborn child. But I think why we thought that was worthwhile was that could potentially benefit Amber personally herself or if not, there's the potential it could benefit other children.  Sharon: Consent has been such a big area of focus for us, Rich, and Rachel touches on that complexity, you know, making a decision on behalf of her unborn child. Can you talk a bit about our approach to consent in the Generation Study and what's evolving in that model?  Rich: Yeah. It's been for the whole study, really, starting out asking a really big question here, what we're aiming to do is generate evidence on whether and if so, how whole genome sequencing should be offered routinely at birth, and that's responding to a really ill need that we know that each year thousands of babies are born in the UK with treatable rare conditions. We will also need to see if whole genome sequencing can make a difference for those families, but we realise to do that, as with all screening, that involves testing more people than are going to benefit from it directly themselves. So, you have to approach it really sensitively. There's lots of complicated questions, lots of nuance in the study overall. One of them is thinking really carefully about that consent process so that families can understand the choices, they can understand the benefits and risks. This is still a research study. We're looking to understand whether we should offer this routinely. It's not part of routine care at this point. The evidence will help decision-makers, policymakers in the future decide that.  At the beginning of the programme, we spent a lot of time talking to families, talking to health professionals who understand the sorts of decisions that people are making at that time of life, but also are experts in helping think about how you balance that communication. That involved, as I say, a lot of conversations. We learnt a lot, lots of it practical stuff, about the stage of pregnancy that people are at when we first talk to them about the study, so that people aren't hurried and make this decision. What we've learnt in the study, right from the outset, is talking to people from midway through the pregnancy so that they really have time to engage in it and think about their choice. So, it's an important part of getting the study design right so that we run the study right. It's also a really crucial element of the evidence that will generate from the study so that we can understand if this is something that's adopted, how should we communicate about it to families. What would they want to know? What's the right level of information and how do we make that accessible in a way that is meaningful to people from different backgrounds, with different levels of interest, different accessibility in terms of digital and reading and so on. There's a lot that we've learnt along the way and there's a lot that we're still learning. And as I say, important things that we'll present as evidence later on.  Sharon: Thank you. It's fascinating there are so many moving parts and a lot to consider when you're building the design of a programme like this or study like this.  Earlier in the year you had a great conversation with Karim Beguir about the developments of AI in genomics. Let's revisit that moment.  Karim: We live in an extraordinary time. I want to emphasise the potential of scientific discovery in the next two or three years. AI is going to move, let's say, digital style technologies like coding and math towards more like science and biology. In particular, genomics is going to be a fascinating area in terms of potential.  Sharon: So, Karim talks about AI moving from maths and coding into biology. Why is genomics such a natural area for AI?  Rich: It's really fascinating. I think it links a lot to how we think about genomics and how you get the most value in terms of health benefit and sort of the progress that we can see could come through genomics more generally. So, your genome, which is your DNA code, written in 3 billion little letters across each one of us, one copied from mum, one copied from dad, even just our genomic code of one person is a large amount of data. That is just part of the story because we're not just interested in DNA for DNA's sake, this is about thinking about health and how we can improve health outcomes. So, it's also thinking about the other sorts of information that needs to link to genomic data to make a difference. Whether that's just to provide routine healthcare with today's knowledge, or whether it's about continuing to learn and discover.  As I mentioned at the beginning, I think a really important part of this whole picture is we've learnt a lot in the last 20/30/40 plus years about genomics. It's incredible how much progress has been made, and we're really just scratching the surface. Take rare disease and the progress that's been made there, it's wonderful how many more families we're able to help today. We know that many thousands of families we still can't find a diagnosis for when we know that there is one there for many of them. That theme of ongoing learning is at the centre of all of our work, and that will continue as we look about broader uses of genomics in other settings beyond rare conditions and cancer. It's also that ongoing learning, but also the amount of, at the moment, manual steps that are required in some of the processes that we need to, for example, find a diagnosis for someone or to make sure the tools that we use are the most up to date, the most up to date with the medical literature, for example. AI is a tool that we're, as the whole of the society, we're beginning to see how it can play a role. We see it as important today for some of the just really practical things. I mentioned it, staying up to date with the medical literature, making sure that we and our systems are aware of all of the knowledge that's coming in from around the world. It's got real potential there.  I think the biggest bottom line here is that it's got the potential to be a really important tool in terms of our ongoing learning and improvement. I'm a doctor by background, the human intelligence alone is fantastic, it's moved us a long way, but we know it also has tremendous blind spots. AI has the potential to complement us there. I guess another thing to really call out here, AI isn't a panacea, it's not suddenly going to answer all of the questions. And, just like human intelligence, it will have its own biases, have its own strong points, and less strong points.  One of the things we're really committed to is working with people like Karim, and many others, to understand where AI could make a difference, to test it, to generate evidence on how well it works and an understanding in all sorts of ways about how that might play out. And, make sure that as AI becomes a tool, that we in genomics, but also in other areas, we understand its strong points and where we need to be more careful and cautious with it. That's a really important part of what we're going to be doing in the coming years here, is making sure that we can maximise the impact of it, but also be confident, so that we can explain to people whose data we might use it on how we're doing it and what it's bringing.  Sharon: Thanks Rich. It's definitely a fast-moving conversation of which we really want to be part of. One of the things that's come up again and again this year is participation and co-production. Let's hear quote that really captures that.  Bobbie: In an earlier conversation with Paul, which you might find surprising that it's stuck with me so much, he used the word ‘extractive'. He said that he'd been involved in research before and looking back on it, he had felt at times it could be a little bit extractive. You come in, you ask questions, you take the data away and analyse it, and it might only be by chance that the participants ever know what became of things next. One of the real principles of this project was always going to be co-production and true collaboration with our participants.  Sharon: That was Professor Bobbie Farsides talking about moving away from extractive research towards true co-production. How are we making that shift in practice here at Genomics England?  Rich: It's a great question. It's one of the areas where I think we've learnt most as an organisation over the years about how really engaging from the beginning with potential participants in programmes, participants who join our programmes, people who are involved in delivering our programmes and healthcare is so important at the beginning. I mentioned earlier the work to think about the consent process for the Generation Study, and that's one of the areas where I think from our first programme, 100,000 Genomes Project, we learnt a lot about how to do that well, some of the pitfalls, some of the bits that are most challenging. And really, right from the start of our programmes, making sure that people who will potentially benefit from the programmes, potentially join them, can be part of that engagement process, and really part of the design and the shaping of the research questions, the parameters around research, but also the materials and how people will engage with them. And that's one of the key capabilities we have internally as an organisation, so we work with partners externally, but also it's a really key part of the team that we have at Genomics England.  Sharon: So, whilst Bobbie talked about moving away from research that can feel one-sided and towards true collaboration, in another episode, Lindsay, a parent of a child with a rare condition, reflected on what that change really means for families and how it's empowering to see their voices and experiences shaping future treatments.  Lindsay: Historically, there's been a significant absence of a patient voice in rare disease research and development. And knowing that that's changing, I think that's really empowering for families. To know that professionals and industry are actually listening to our stories and our needs and really trying to understand, that offers much greater impact on the care and treatments of patients in the future.  Sharon: So, what role do you see participants as partners in shaping the next phase of Genomics England's work?  Rich: So, as you probably detected from my last answer, we see it as absolutely vital. One of the really exciting things here at Genomics England, we've had a participant panel from very early in our life as an organisation. That's one really important route to us at the heart of our organisation, part of our governance, making sure that participants representing all sorts of parts of our programme, but rare conditions being a really large focus for us. And I think, what's so striking as someone with a medical and a research background can see how I think historically medics and researchers have sometimes not known, sort of maybe been a bit scared about knowing how to involve participants from the outset. Often, because they're worried that they might ask the wrong questions in the wrong way, they just don't have the tools.   One of the things I often say now to people we work with is one of the most empowering and positive experiences we have at Genomics England is the power of our participants helping to, right from the beginning, shape what the questions are that we should be asking. Realise some of the challenges that you can't possibly, if you're not in their shoes, understand are the most important to really shape how we prioritise our work internally, the problems that we need to solve first, how we think about some of the practical impacts on people's lives that, again, without hearing from their voice you just wouldn't know. And again, to help our researchers, people accessing data in the National Genomic Research Library, helping them make sure that they involve participants in their work and the confidence and tools to do that.  Sharon: That's great, thank you. Another big theme this year has been collaboration across the NHS, academia, and industry. Dr Raghib Ali puts this really well.  Raghib: There are areas where academia and the NHS are very strong, and there are areas where industry is very strong, and why working together, as we saw, you know, very good examples during the pandemic with the vaccine and diagnostic tests, etc., a collaboration between the NHS, academia, and industry leads to much more rapid and wider benefits for our patients and, hopefully, in the future for the population as a whole in terms of early detection and prevention of disease.  Sharon: So, how does collaboration fit into the 10-year health plan and what's next for 2026 in that space, Rich?  Rich: I think one of the most enjoyable parts of my role at Genomics England and our role as an organisation is the fact that we see ourselves very much as part of a, sort of team across the UK and in fact internationally in terms of delivering on the potential we see for genomics. So, we have a vision as an organisation, which has been the same the last 5 or so years, which is a world where everyone can benefit from genomic healthcare. In fact, that vision is now shared by the NHS from a genomics perspective, and really demonstrably, the 2 parts of the system absolutely pointing in the same direction. And when we've been thinking, looking forward with that 10-year lens on it, what we always like to do, and I think it's a real privilege to be able to do, because we're here in the UK, because we have a National Health Service, because there's been that long-term commitment from government on genomics and really taking a long-term investment view there, and because of so many other parts of the ecosystem, other experts who access data in the National Genomic Research Library, research organisations like Our Future Health, UK Biobank, all teaming together, and the expertise that's there in genomics more broadly. So we've, if you like, worked back from what the UK could do as whole, and in the 10-year health plan, as I said earlier, genomics is at the heart of that.  There's a double helix on the front cover and, in fact, on the watermark on almost every page. And, there's this view set out there where as many as half of all health interactions by 2035 could be informed by genomics or other similar advanced analytics. And we think that that's a really ambitious challenge. We see a really important role for us, as Genomics England, in contributing to that, but it's very much a team effort. Our role is around where we have the biggest capabilities, so around building and running digital infrastructure at a national scale for healthcare delivery and for research, to building evidence to inform future policies, so running programmes like the Generation Study to inform future policy. And really, as part of that, that evidence piece, being driven by engagement, ethics, and work on equity, to really make sure that evidence that future policy can be built on is informed by a fully rounded view. We think if we do that right that we could as a country with others, the NHS, research organisations, many others could live up to that ambition that's set out there in the 10-year plan.   And the 10-year plan is really clear, and government is really clear that this is about improving health outcomes. But it's also part of a broader benefit to the country because the UK is recognised already as a great place from a genomics perspective. We think playing our role in that won't just bring the health benefits, it also will secure the country's position as the best place in the world to discover, prove and where proven role out benefit from genomic innovations. And we think it's so exciting to be part of that team effort.  Sharon: So, Genomics England's refreshed mission and direction of travel is really setting out how we move from research to routine care, and how we embed genomics across the health system. Carlo Rinaldi captured the idea perfectly, imagining a future where diagnosis and hope arrive hand in hand.  Carlo: My dream is that in five to ten years' time an individual with a rare disease is identified in the clinic, perhaps even before symptoms have manifested. At that exact time the day of the diagnosis becomes also a day of hope, in a way, where immediately the researcher, the genetic labs, flags that specific variant, that specific mutation. We know exactly which is the best genetic therapy to go after.   Sharon: And Rich, what are your thoughts on that?  Rich: I think Carlo captures it really well. And for us, I think a really big theme is for that potential for genomics to make a difference, a continued and in fact increased difference for people with rare conditions and cancer, areas where it's already making a difference, but also with the potential to make a much broader impact for people across the population. The real theme is embedding genomics into routine care, making it something that you don't need to know that you're seeing an expert in genomics to benefit from it, really make sure that those benefits can be felt as just part of routine care. It's not something separate where we recognise that the best healthcare is healthcare that's supported by all sorts of inputs, with genomics being a key part of that, and that we can continue to learn as we do that. So that with people's consent, with their understanding of how their data is being used, we know that if we don't have the best answer for them today, we give the best answer we can today, and we can continue to learn, and they can benefit from that in the future.   I'm a rare disease doctor by background, and one of the really most enjoyable parts of my job is seeing that come to practice. In the last year or so I've had a number of families where I've been seeing the family for years, and a researcher accessing data in the National Genomic Research library has found an answer that we've not been able to find for maybe their child's whole life, and then finally we're able to feed it back. Seeing that come to life is just so wonderful, and I think gives us a bit of a blueprint for how things could work more generally.  Sharon: That's great. I mean, what a feeling for those families who do get those answers. As we look ahead to 2026 and beyond, the conversation is starting to include prevention, using genomics not just to diagnose conditions but to predict and treat and even prevent them. Alice Tuff-Lacey summarised this nicely in an episode about Generation Study.  Alice: This is quite an exciting shift in how we use whole genome sequencing, because what we're talking about is using it in a much more preventative way. Traditionally where we've been using it is diagnostically where we know someone's sick and they've got symptoms of rare condition, and we're looking to see what they might have. What we're actually talking about is screening babies from birth using their genome to see if they're at risk of a particular condition. And what this means is this raises quite a lot of complex ethical, operational, and scientific and clinical questions.  Sharon: Rich, when you think about 2026, what's your biggest hope for where we'll be this time next year?  Rich: I think it's a really exciting time. As you can tell from how we've been speaking, I'm really excited about the direction of travel and how over the next 5 and 10 years we can really make a transformational shift because of how well placed we are in the UK from a genomics perspective. Where we are with today's knowledge, where we could be because of the continued government and NHS commitment to genomics being at the heart of this, if we build the right infrastructure, if we generate the right evidence to inform what's adopted, I think we're in a really exciting place.  From a 2026 perspective, I think what we're really committed to is continuing to do the work, the day-by-day-by-day work that is to build that incrementally. So, a really big focus for us is continuing to support the NHS and making sure researchers can access data, so that flow of answers for families can continue and grow, accelerate, to continue delivering the Generation Study because it's a really important part of that wider jigsaw to generate the evidence that can inform future policy on whether this is something that's adopted and offered routinely to every child when they're born.  I think a really important time now that the government's provided the opportunity for us as a team, as a UK genomics and life sciences ecosystem, is to really put in place some of the next steps, the building blocks that can take us towards that 10-year vision. So for us also, a really important part of the year is beginning the design process for an adult population genomics programme, where we're looking at what evidence it's important that we can provide that's complementary to different work around by others in the ecosystem that needs to be there if we're going to think about that potential broader use of genomics.  Sharon: That's great. It sounds like another exciting year ahead. So, we're going to wrap up there. Thank you to Rich Scott for sharing your reflections on the key milestones this year, and for your thoughts on the year ahead. Thanks, Rich.  Rich: Thanks very much for having me.  Sharon: If you enjoyed today's episode, we'd love your support, so please subscribe, share, and rate us on wherever you listen to your podcasts. I've been your host, Sharon Jones. This podcast was produced by Deanna Barac and edited by Bill Griffin at Ventoux Digital. Thank you for listening. 

Dr. Alexandra Markou-Guzman is a pediatric dentist who works in a public health center treating children from a Hasidic Jewish population in New York City. She shares her experience working with this population, and the cultural challenges that come with it. We discuss some of the unique dental considerations that come into play with treatment planning and working with these families. Dr. Alex is a recent graduate of an NYU residency. She shares how she was able to apply for and receive a National Health Service scholarship to help pay for school. By qualifying for this scholarship and completing two years of work in public health, she was able to significantly reduce her student loan burden.

Welcome to the Planet MicroCap Podcast's Due Diligence series. I'm your host, Robert Kraft. My guest today is Dan Goldberger, CEO of electroCore (NASDAQ: ECOR). electroCore is a commercial-stage neuromodulation company developing a suite of non-invasive vagus nerve stimulation devices—delivering a two-minute therapy session designed to rebalance the autonomic nervous system. Built around its nVNS platform, the company operates across three channels: prescription medical devices for headache and migraine, the fast-growing Truvaga direct-to-consumer wellness brand, and a specialized military and government division built around its ruggedized tac-stim product.   Founded in 2006 as a non-invasive alternative to implanted vagus nerve stimulators, electroCore has evolved into a multi-indication business with seven FDA authorizations for headache, serving major customers like the U.S. Department of Veterans Affairs and the UK's National Health Service. I invited Dan to the show to discuss all of this, as well as: How nVNS platform works and the science behind vagus nerve modulation electroCore's evolution from implanted alternatives to multi-channel neuromodulation The prescription business model across the VA, NHS, and managed care Truvaga's growth in the wellness market and why awareness is the primary competitor The tac-stim military program and its role as a meaningful revenue stream Strategic priorities heading into 2026—profitability, capital allocation, and commercial execution Challenges around insurance coverage and overcoming the “chicken and egg” problem The path toward becoming a $150–200 million business and the long-term vision for the platform For more information about electroCore, please visit: https://www.electrocore.com/ This podcast was recorded and is being made available by SNN, Inc. (together with its affiliates and its and their employees, “SNN”) solely for informational purposes. SNN is not providing or undertaking to provide any financial, economic, legal, accounting, tax, or other advice in or by virtue of this podcast. The information, statements, comments, views, and opinions provided in this podcast are general in nature, and such information, statements, comments, views, and opinions, and the viewing of/listening to this podcast are not intended to be and should not be construed as the provision of investment advice by SNN. The information, statements, comments, views, and opinions expressed in this podcast do not constitute and should not be construed as an offer to buy or sell any securities or to make or consider any investment or other course of action. The information, statements, comments, views, and opinions expressed in this podcast (including by guest speakers who are not officers, employees, or agents of SNN) are not necessarily those of SNN and may not be current. Reference to any specific third-party entity, product, service, materials, or content does not constitute an endorsement or recommendation by the SNN. SNN assumes no responsibility or liability for the accuracy or completeness of the content contained in third party materials or on third party sites referenced in this podcast or the compliance with applicable laws of such materials and/or links referenced herein. The views expressed by guest speakers are their own and their appearance on this podcast does not imply an endorsement of them or any entity they represent. SNN does not make any representation or warranty as to the accuracy or completeness of any of the information, statements, comments, views, or opinions contained in this podcast, which may include forward-looking statements where actual results may differ materially. SNN does not undertake any obligation whatsoever to provide any form of update, amendment, change, or correction to any of the information, statements, comments, views or opinions set forth in this podcast. SNN EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING OUT OF ANY INDIVIDUAL'S USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE, THIS PODCAST OR THE INFORMATION PRESENTED IN THIS PODCAST. By accessing this podcast, the listener acknowledges that the entire contents and design of this podcast, are the property of SNN, or used by SNN with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this podcast may save and use information contained in the podcast only for personal or other non-commercial educational purposes. No other use, including without limitation, reproduction, retransmission, or editing of this podcast may be made without the prior written consent of SNN.

In this week's episode we're taking a close look at the New Hospital Programme, a programme which has been described as perhaps the most ambitious National Health Service infrastructure investment in decades.The NHP programme is tasked with delivering a new generation of state-of-the-art hospitals across England. At its core is Hospital 2.0, a standardised, repeatable and industrialised approach to hospital design and delivery that promises greater certainty, faster construction, improved quality, predictable costs, and cutting-edge clinical environments. To explain the programme and how it will be delivered, I am joined by Doug Baldock, Technical Services Director, and Emily King, Director of Industrialisation at the NHP, two leaders central to shaping the technical, commercial and industrial strategy underpinning Hospital 2.0. And with a long-term pipeline backed by rolling five-year funding envelopes averaging around £3 billion a year from 2030, the programme aligns with the Government's wider Industrial Strategy and aims not only to modernise the NHS estate but to boost innovation, strengthen supply chains and support economic growth across the UK.The scale of this challenge is immense: dozens of complex hospital schemes, varied site conditions, urgent RAAC rebuilds – and, of course, the need to rebuild public and industry confidence after years of delay and uncertainty. Yet with clearer planning assumptions, a 12-year £37bn Hospital 2.0 Alliance procurement, and deep engagement with suppliers, the programme now seeks to unlock the capability and investment needed for a sustainable long-term programme.Well let's find out what it means in reality..Resources New Hospital Programme: Plan for ImplementationGovernment hospital investment press release Supplier Guide.Egan review 1998Latham review 1994

There is a world of difference between the NHS from its beginnings in 1948 and the NHS as it is now. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ruth Chambers OBE, co-director of Raparu Consult CIC and a visiting professor at Staffordshire University, for a conversation on her book, “Our NHS for better or worse?”. Chambers discusses her personal experience as a GP in the NHS, including the discrimination she faced as a woman, and analyses the notion of ‘burden' in respect of the National Health Service, as well as differences in mental health care now and her proposed ‘Prescription for Change'. You can listen to episode 228 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

This special Christmas episode captures a moment in time – a warm and reflective conversation with my dad, Gary, recorded with his loyal sidekick Hobbs the dog, who makes his presence known but settles down after about 5 minutes. With Christmas approaching, I wanted to step back and explore what the festive season felt like in the 1950s – when Dad was growing up in a terraced house in Leeds, the National Health Service was brand new, and festivities were shaped far more by family and imagination than by spending. Across the episode, Dad paints a vivid picture of Christmas Eve plays staged in their tiny kitchenette, paper-chain decorations, walk-to-grandma traditions, and the excitement of having the whole family under one roof. We talk about presents, pubs you couldn't take children into, cars with no seatbelts, and rituals that meant far more than the gifts themselves. It is also a gentle reminder that the memories that last are the simplest ones – cooking together, laughing together, being together. As Dad says, the details stay with you forever, long after the people have gone. If you need a moment of nostalgia, grounding or perspective in the build up to Christmas, this is a lovely listen.

In case you didn't see our major announcement this week… The OCTOBER 7 play is having its most high profile performance to date! You won't believe where it will be showing next. Hint: It's right in the belly of the beast and we want to see you there. All will be revealed soon. And just when we thought the trans madness was dying in the UK, we discover that the Dr Frankensteins/Mengeles of the world are alive and well in that country's National Health Service. They want to recruit 250 humans for gender experiments.Oh but don't worry, these patients/victims will be at least at the ripe old age of 10, and totally understand what they're in for. Of course they can give informed consent. Not. Watch the Scoop this week to hear about the latest attack on children whose bodies are being destroyed on the altar of progress. And our home country of Ireland is constantly proving that it is the most anti-Semitic country in Europe. Now they've somehow sunk to a new low by deciding to rename a park, which was dedicated to a local Jewish hero. Dublin City Council's scheme was thwarted by a technicality, for now… Watch this week's episode to get all of the infuriating details. You can also learn more through Phelim's coverage on Substack(linked below).And in Crazy California, we reveal why the homeless problem will never be solved. It's because Democrats are making just too much money maintaining the problem - as the rest of us suffer from their corruption.And is Ann McElhinney safe to drive on the nation's roads? According to the DMV - she is a danger. If it's true, then how did hundreds of thousands of Indian immigrants get truck driving licenses when they obviously were not qualified? Watch this week to hear our answer. And we have a new “no recipe recipe” for salmon this week. Watch this week to learn how to make one of Ann's favorite dishes. You will also need Ann's recipe for Kale Salad(linked below) for a side and we let you in on our secret for the perfect French Fries. For those who missed last week's episode, we looked back at the first Thanksgiving episode of the ANN AND PHELIM SCOOP when we interviewed our dear friend, Dennis Prager. Dennis, who has suffered a catastrophic injury, is the embodiment of the spirit of Thanksgiving and our interview with him and hearing his message promoting happiness and gratitude still warms the heart. Dennis has had a tough time since then, but he says he is still thankful to be alive. As you know we read all of your comments and loved all of the encouragement that you sent his way. We will be passing on your messages to Dennis.Watch the episode where we will read some of those comments on the air. Please keep leaving comments wherever you get our content and you may get a shoutout on our show. While you will be getting this message after Giving Tuesday, we do ask that you go to Unreportedstorysociety.com(also linked below) and give what you can so that we can keep producing new projects, and keep our latest projects like OCTOBER 7 the play running. We are a 501(c)(3) so your donation will be tax deductible.If you want to see OCTOBER 7 the play come to a location near you please donate at October7theplay.com(also linked below). And if you are already doing your Christmas shopping and waiting in another loooong line at the mall, please consider subscribing to our Stories.io substack(linked below) so that you can get informed and engaged in matters that we talk about beyond just our weekly show.To donate click here:To subscribe to our substack click here:To help us continue to tour OCTOBER 7 the play, please go here:http://October7thePlay.com To read Phelilm's latest substack about anti-Semitism in Ireland click here. To make Ann's kale salad recipe click here:

Dr. Colin Robertson suggests we look at our lives on a day to day basis making sure that we are "earning our dopamine" in a way that creates long term benefits, mixing nature into our daily routine, and creating health that allows us to wake up painless.Some key takeaways from the conversation:Health, wellness, and fitness are fundamental building blocks of a life worth living, more important than financial wealthPhysical health enables people to fully experience life and create lasting memoriesThe gut is "the center of the human universe" - optimizing gut health has multiplying effects on all other aspects of healthNatural, unprocessed foods are essential for proper gut function and overall healthActive experiences in nature create deeper, more lasting neural connections than passive screen-based activitiesTesting gut health provides objective data to guide personalized health improvementsDr. Colin Robertson (Dr. Col) is an environmental physiologist with a PhD in Exercise Physiology who helps translate cutting-edge sport science into practical strategies for athletes, adventurers, and everyday health seekers. For more than two decades, he has helped shape health strategies and standards for organizations worldwide, including EuropeActive, UKactive, and the National Health Service. A specialist in human performance and sports science, he has coached and prepared global adventurers to tackle extraordinary challenges, from climbing Everest to rowing the Atlantic, and supported athletes in strength and conditioning across various sports, including rugby, wrestling, and wheelchair basketball, in national and international competitions. He is an accredited Strength and Conditioning Coach (UKSCA), accredited Kinanthropometrist, and a qualified Nutritionalist, blending elite-level sport science and clinical health research into practical lifestyle strategies. His research is widely published in peer-reviewed scientific journals, including co-authoring the notable Sleep and the Athlete: Narrative Review and 2021 Expert Consensus Recommendations (British Journal of Sports Medicine, 2021). He also co-hosts the Common Knowledge podcast, a go-to channel for useful and meaningful health and lifestyle information that is free and accessible to everyone. Zinzino is a global health tech company from Scandinavia, pioneering products and services in the health and wellness space for over two decades. Driving a new standard in personal health, the company's test-based, personalized nutrition approach provides tools for a healthier future by enabling individuals to take charge of their personal well-being through science-based insights and targeted solutions. Offerings include a portfolio of advanced at-home health tests and an extensive range of nutritional supplements scientifically proven to meet individual needs. Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

The UK's consumer healthcare industry association, PAGB is publishing a series of blog posts for Self-Care Week – an annual awareness campaign in the UK organized by the Self Care Forum, held this year from 17-23 November. In this second part of a special episode of HBW Insight's Over the Counter podcast, we catch up with the association's CEO Michelle Riddalls, to talk about what the association is doing to promote digital health. As part of the UK government's plans for reforming the country's National Health Service, PAGB is asking for the widely used UK NHS app to not only advise people on how to self-care but also to take users to OTC brand websites that can help them to self-manage their conditions appropriately. We also discuss the advantage of having digital apps and self-care information generally linked to trusted umbrella brands. Timestamps 2:00 – PAGB's digital health strategy 6:00 – The NHS app and self-care brands 12:00 – Self-care apps 15:30 – The importance of brands Guest Bio Michelle Riddalls OBE is chief executive officer of PAGB, the consumer healthcare association, which represents the manufacturers of branded OTC medicines, self-care medical devices and food supplements in the UK. Prior to joining PAGB, Riddalls was director of regulatory affairs for the Northern European Cluster at Pfizer Consumer Healthcare, where she was integral in the highly successful POM to GSL reclassification of Nexium Control and the Viagra Connect POM to P switch. Michelle has been recognized across a number of industry awards, including the Women in Trade Powerlist in 2024, and was awarded an OBE for outstanding services to consumer health in the King's 2025 New Year Honours.

Peter McCue worked for many years as a clinical psychologist in the National Health Service in the UK. He lives in Scotland. His qualifications include a Ph.D., from the University of Glasgow, awarded for a thesis based on research into the nature of hypnosis. His interest in psychical research goes back decades. He believes that paranormal phenomena occur, and that many UFO experiences are genuinely anomalous. He contends that if we want to obtain a comprehensive understanding of ourselves and the nature of reality, these enigmatic phenomena can't be ignored. Peter is the author of a recently published book, entitled Zones of Strangeness: An Examination of Paranormal and UFO Hot Spots.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-x-zone-radio-tv-show--1078348/support.Please note that all XZBN radio and/or television shows are Copyright © REL-MAR McConnell Meda Company, Niagara, Ontario, Canada – www.rel-mar.com. For more Episodes of this show and all shows produced, broadcasted and syndicated from REL-MAR McConell Media Company and The 'X' Zone Broadcast Network and the 'X' Zone TV Channell, visit www.xzbn.net. For programming, distribution, and syndication inquiries, email programming@xzbn.net.We are proud to announce the we have launched TWATNews.com, launched in August 2025.TWATNews.com is an independent online news platform dedicated to uncovering the truth about Donald Trump and his ongoing influence in politics, business, and society. Unlike mainstream outlets that often sanitize, soften, or ignore stories that challenge Trump and his allies, TWATNews digs deeper to deliver hard-hitting articles, investigative features, and sharp commentary that mainstream media won't touch.These are stories and articles that you will not read anywhere else.Our mission is simple: to expose corruption, lies, and authoritarian tendencies while giving voice to the perspectives and evidence that are often marginalized or buried by corporate-controlled media

#MEDICALINNOVATION #OLYMPICSWIMMING #championmindset This is an inspirational keynote presentation on October 6, 2025, at the Opening Ceremony of the 2025 Medical lnnovation Olympics from Chris Cook, double Olympian swimmer, double Commonwealth Games Champion, World Championship Bronze Medalist, motivational speaker at companies such as Microsoft and some of the largest health systems across the globe, and consultant to the U.K.'s government's National Health Service.Chris shares three specific personal stories that span Olympic level training, building the next generation of Olympic champions, and transformation of teamwork across a Healthcare system with psychological safety.0:00 Timeline - Highlights2:12 - Intro: 3 Key Messages - Evidence-based Confidence, Clarity, and Psychological Safety3:28 - Biggest lesson on Confidence during the Toughest Season (2006)4:57 - Measure what Matters: Heart Rate, Stroke Rate, Time, Perceived Exertion5:35 - Challenge: Beat the Average from Previous Week5:51 - Turning Point: Started to be obsessed with Progress7:10 - Leadership Phase after Retirement7:27 - Ambition Programme - Team Great Britain - less than 8% of first time Olympians medal, intense build-up, media attention of the Olympics8:35 Pilot Project of First-time Olympians Created environment for potential stars to feel like Olympians, media mock-interviews, etc.9:41 Ambition Programme Alumni & Results307 athletes have finished this program40% represent Team GB 11% of the athletes in the program win a medal10:12- When we get clear we level up certainty Ask it, answer it, and action it - the last one drives certainty10:50 - Collaboration with the National Health Service in the UKNew programs: 1) Creating Psychological Safety to share, contribute, and debate; 2) Radical Candor. In less than 18 months, the pilot transformed one department, then started to spread12:34 - Teamwork thrives on Psychological Safety12:56 - Keynote SummaryConfidence is built from evidenceWhen we are unclear, things become uncertain - Challenge to the audience!True teamwork starts when we are safe to take risks

#656: What would you do if someone in authority told you to do something that felt wrong? Most of us like to think we'd speak up, push back, stand our ground. But research tells a very different story. In fact, when Yale researchers conducted a famous experiment in the 1960s, they found that 65% of people would administer what they believed to be deadly electric shocks to another human being... simply because someone in a lab coat told them to. Today's guest has spent over 15 years studying why humans comply with authority - even when every fiber of our being is screaming that we shouldn't. And when it comes to our money, this tendency to comply with authority figures - from financial advisors to real estate agents to car salespeople - can cost us dearly. Dr. Sunita Sah began her career as a physician in the UK's National Health Service. During one particularly exhausting period as a junior doctor, she agreed to meet with a financial advisor who had contacted her at work. That meeting sparked questions that would shape the rest of her career: Why did she feel pressured to trust this advisor, even after learning he had a conflict of interest? Today, she's a tenured professor at Cornell University, where her groundbreaking research on compliance and influence has been featured in The New York Times and Scientific American. She's advised government agencies, served on the National Commission on Forensic Science, and helps leaders understand the psychology behind why we say "yes" when we really want to say "no." Whether you're meeting with a financial advisor, negotiating the price of a home, or discussing rates with a contractor, understanding the psychology of compliance could save you thousands of dollars - and help you make better financial decisions. Today's conversation isn't just about psychology - it's about protecting your wealth by learning when and how to say "no." Resources Mentioned in the Episode: - Website: sunitasah.com - Newsletter: Defiant By Design | Dr. Sunita Sah | Substack - Connect with Dr. Sunita Sah - Follow Dr. Sah on Instagram About Dr. Sunita Sah Dr. Sunita Sah is a tenured professor at Cornell University specializing in organizational psychology. Her research focuses on how and why people comply with authority, even against their better judgment. A former physician in the UK's National Health Service, Dr. Sah brings a unique perspective to understanding human behavior and decision-making. Her work has been featured in leading publications including The New York Times and Scientific American, and she has served as a Commissioner on the National Commission on Forensic Science. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This is a free preview of a paid episode. To hear more, visit www.louiseperry.co.ukMy guest today is Dan Hitchens, senior editor at First Things Magazine. We spoke about assisted suicide: the second and third order consequences of legalisation, why low fertility welfare states are increasingly drawn to this apparent solution to their financial woes, and why Britain's National Health Service would prove to be a particularly dangerous p…

In this explainer episode, we've asked Dr Emily Perry, research engagement manager at Genomics England, to explain what the Genomics England Research Environment is. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. You can listen to the previous episodes mentioned in this podcast How has a groundbreaking genomic discovery impacted thousands worldwide? What is the National Genomic Research Library If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What is the Genomics England Research Environment? My name is Florence Cornish and I'm here with Emily Perry, Research Engagement Manager at Genomics England, to find out more. So Emily, before we dive into the Research Environment, let's set some context. Could you explain what Genomics England is aiming to do as an organisation? Emily: So, Genomics England provides genome sequencing in a healthcare setting for the National Health Service in England. As we sequence genomes for healthcare, the benefit is that we can also put that genomic and clinical data out for research in a controlled manner, and then that can also feed back into healthcare as well. So, it's really, this kind of cyclical process that Genomics England is responsible for. Florence: And so, what do we mean when we say Research Environment? Emily: So, the Research Environment is how our researchers can get access to that clinical and genomic data that we get through healthcare. So, it's a controlled environment, it's completely locked down, so it's kind of like a computer inside a computer. And in there, the researchers can access all of the data that we have and also a lot of tools for working with it in order to do their research. We refer to the data as the National Genomics Research Library, or the NGRL. The NGRL data is provided inside the Research Environment Florence:  So you mentioned the National Genomic Research Library. If any listeners want to learn more about this, you can check out our previous Genomics 101 podcast: What is the National Genomic Research Library? And so Emily, could you talk about what kind of data is stored in this library? Emily: So the library is made up of both genomic data and clinical data, which the researchers use alongside each other. The genomic data includes what we call alignments, which is where we match the reads from sequencing onto a reference sequence, and variants, which is where we identify where those alignments differ from the reference sequence, and this is what we are looking for in genomic research. The clinical data includes the data that was taken from our participants at recruitment, so details of the rare disease, the cancer, that they have, but also medical history data. So, we work with the NHS and we're able to get full medical history for our participants as well. This is all fully anonymised, so there's no names, there's no dates of birth, there's no NHS numbers. It's just these identifiers which are used only inside the Research Environment and have no link to the outside world. Florence: And so how is this clinical and genomic data secured? Emily: So, as I said there's no names, there's no NHS numbers, there's no dates of birth.  And we have very strict criteria for how people can use the data. So researchers, in order to get access to the Research Environment, they have to be a member of a registered institution, they have to submit a project proposal for what it is that they want to study with the data. There's also restrictions on how they can get the data out, so they do all their research inside, there's no way that they can do things like copy and paste stuff out or move files. The only way that they can get data out of the Research Environment is going through a process called Airlock, which is where they submit the files that they want to export to our committee, who then analyse it, check that it's in accordance with our rules and it protects our participants' safety and that only then would they allow them to export it. Florence: Who has access to the Research Environment? Emily: We have researchers working with the Research Environment all over the world. There's 2 kind of major groups. One of them is academia, so this will be researchers working in universities and academic institutions. The other side of it would is industry - so this will be biotech, startups, pharma companies, things like that. Florence: And finally, can you tell us about some of the discoveries that have been made using this data? Emily: There's lots of really cool things that have come out of the Research Environment.  A recent story that came out of the Research Environment was the ReNU syndrome, it was initially just one family that they identified this in, and they were able to extend this discovery across and identify huge numbers of individuals who had this same disorder because they had their genomes within the Research Environment. Florence: You can hear more about this research in our previous Behind the Genes podcast: How has a groundbreaking genomic discovery impacted thousands worldwide? So, we'll wrap up there. Thank you so much, Emily, for sharing more about what we mean by the Genomics England Research Environment. If you'd like to hear more explain episodes like this, you can find them on our website, at www.genomicsengland.co.uk or wherever you get your podcasts. Thank you for listening.  

Aneurin Bevan's commitment to social justice led to the creation of the National Health Service in 1948 – one of the most ambitious social reforms in British history. He was an MP who stuck to his principles in the face of serious opposition, but was not without criticism in both his professional and personal life. Speaking to Lauren Good, Nye Davies charts Bevan's journey from the coalfields of South Wales to the corridors of Westminster. The HistoryExtra podcast is produced by the team behind BBC History Magazine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to this week's episode of the PEBCAK Podcast!  We've got four amazing stories this week so sit back, relax, and keep being awesome!  Be sure to stick around for our Dad Joke of the Week. (DJOW) Follow us on Instagram @pebcakpodcast   Please share this podcast with someone you know!  It helps us grow the podcast and we really appreciate it!   2016: The Dawn of Modern Ransomware The debut of Petya and Russian-affiliated groups like CryptoWall, TeslaCrypt, and Locky. Attacks were largely indiscriminate, targeting anyone from Fortune 500 companies to "Grandma's laptop." Early mitigation tactics, like installing Russian language packs to avoid infection, highlighted the state-tolerated nature of these groups.   2017: Ransomware Goes Mainstream A pivotal year with the WannaCry attack (attributed to North Korea's Lazarus Group) and NotPetya (Russian-backed), causing billions in damages to companies in multiple verticals. The SAMSAM attacks hit U.S. cities like Baltimore and Atlanta, marking Iran's brief foray into ransomware. Ransomware became a household name, sparking executive-level discussions in boardrooms.   2020: The Rise of Ransomware-as-a-Service Groups like Ryuk, REvil, and Conti refined ransomware into a business model, outsourcing tasks like initial access and money laundering. Double extortion emerged, with attackers stealing data and threatening to leak it, even if backups were restored. Some groups introduced “terms of service,” avoiding hospitals and schools to dodge law enforcement scrutiny.   2021: Critical Infrastructure in the Crosshairs High-profile attacks on Colonial Pipeline, JBS Foods, and Ireland's National Health Service disrupted daily life, from gas shortages to meat supply issues. These incidents underscored ransomware's real-world impact, elevating cybersecurity to a boardroom priority.   2022: Geopolitical Shifts and New Players Russian-backed groups like Conti and LockBit shifted focus to Ukraine amid the Russia-Ukraine conflict. The rise of Scattered Spider, a Western-based group excelling at social engineering and SIM swapping, marked a shift from Eastern state-tolerated actors.   2023: Trust Breaks Down The ALFV/BlackCat group's $22 million rug pull against affiliates signaled the decline of Russian-backed ransomware dominance. Scattered Spider solidified its reputation, targeting major hospitality and cleaning companies with sophisticated social engineering tactics.   2025: The Western Cybercrime Surge Scattered Spider and affiliates like DragonForce dominate, hitting retailers, insurance, aviation, and automotive sectors. The shift to Western-based actors, often young and operating in Five Eyes nations, makes them more vulnerable to law enforcement.   Trends and Takeaways The move from expensive zero-day exploits to cheaper n-day exploits and social engineering highlights attackers' adaptability. Double extortion and even “double dipping” (demanding additional ransoms months later) have become standard tactics. The accessibility of AI tools and open-source platforms like Venice AI has lowered the barrier for creating ransomware, even for non-programmers. Law enforcement's increasing success in arrests and Bitcoin recovery (e.g., DarkSide's downfall) offers hope for curbing cybercrime.       Dad Joke of the Week (DJOW)   Find the hosts on LinkedIn: Chris - https://www.linkedin.com/in/chlouie/ Ben - https://www.linkedin.com/in/benjamincorll/

In this episode with Luke Murray we discuss Paul Ingraham's e-book on plantar fasciitis. We cover:Common causes of plantar fasciitisIs stretching effective for plantar fasciitis?Strengthening for the treatment of plantar fasciitisAnd more!

Roughly 1 in 10 Americans take antidepressants. The most common type is SSRIs, or  selective serotonin re-uptake inhibitors, like Prozac, Lexapro, and Zoloft. But what happens when you stop taking them? Studies don't point to a single conclusion, and there's ongoing debate among physicians and patients about the severity and significance of SSRI withdrawal symptoms. The discourse reached a fever pitch when Health Secretary Robert F. Kennedy Jr. compared SSRI withdrawal to heroin withdrawal in January.Host Flora Lichtman digs into the data on SSRI withdrawal with psychiatrists Awais Aftab and Mark Horowitz.Guests: Dr. Awais Aftab is a clinical associate professor of psychiatry at Case Western Reserve University.Dr. Mark Horowitz is a clinical research fellow in the UK's National Health Service and  scientific co-founder of Outro Health.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

This episode of Integrative Cancer Solutions Dr. Karlfeldt features an in-depth conversation with Sarah Marsh, a representative of Genesis Care in the UK, focusing on the integration of exercise medicine into cancer treatment. Sarah introduces Genesis Care's services, which include private chemotherapy, radiotherapy, and immunotherapy across 14 centers, and shares her personal connection to cancer through her husband's experience. She emphasizes the organization's commitment to a personalized approach, offering patients a 12-week exercise program designed to improve strength, manage side effects like fatigue and nausea, and enhance overall quality of life. The discussion explores the differences between private and public healthcare systems in the UK and Sweden, highlighting how Genesis Care collaborates with the National Health Service and runs clinical trials that benefit both sectors. Sarah explains that her five-year tenure at Genesis Care has given her insight into the unique needs of cancer patients, particularly the importance of meeting patients where they are and gradually reintroducing exercise routines that may have been disrupted by diagnosis and treatment. A significant portion of the conversation centers on the evidence supporting exercise as a critical component of cancer care. Sarah details how personalized exercise programs, including strength and balance training, can reduce the risk of cancer recurrence and help patients regain confidence and physical capability. She stresses the importance of flexibility and accessibility, encouraging patients to start with small steps and build up their activity levels as they feel able. Beyond exercise, the episode delves into the adjunctive therapies and wellbeing services offered by Genesis Care, such as acupuncture, reflexology, sleep assistance, and menopause support. These services are integrated into the overall treatment plan to address symptoms like hot flushes and fatigue, providing a holistic approach to patient care. Sarah shares that patients who complete the 12-week program often see significant improvements in both strength and quality of life. The conversation concludes with practical advice for cancer patients and their families. Sarah encourages patients to advocate for themselves, seek information, and involve loved ones in their care journey. Drawing from her husband's experience, she underscores the value of structured exercise and a supportive network, reminding listeners that it is never too late to start moving and that every small effort contributes to improved wellbeing and resilience during cancer treatment.Sarah Marshall from Genesis Care UK discusses the benefits of integrating exercise medicine into cancer treatment, emphasizing personalized 12-week programs for patients.Genesis Care offers private chemotherapy, radiotherapy, and immunotherapy services across 14 centers, collaborating with both public and private healthcare sectors.Exercise is shown to help manage side effects like fatigue and nausea, reduce the risk of cancer recurrence, and improve patients' strength and quality of life.Additional wellbeing services such as acupuncture, reflexology, and sleep assistance are provided to support holistic patient care.Sarah encourages cancer patients to advocate for themselves, start with manageable exercise routines, and seek support from professionals and loved ones.Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Story 1: The term “fascist” has become the go-to insult among politicians and political steamers as of late, but how many of them understand the definition behind it? Will breaks down what the true definition of fascism is and explains how its misuse can potentially embolden some to commit acts of violence. Story 2: Congressman Andy Barr (R-KY) joins Will to discuss the rise in support for socialism in Democrats across the country, and the ripple effect it has had amongst the Democratic Party's politics. Plus, Rep. Barr and Will react to a viral clip of Kentucky legend Colonel Sanders' great-great-great nephew denouncing KFC's risqué marketing, before proceeding to reveal what he claims are the secret 11 herbs and spices. Story 3: Host of ‘The Rubin Report,' Dave Rubin helps Will break down the bizarre support from the UK's National Health Service for first cousin marriage, which they now claim leads to stronger social support systems and economic advantages? Will and Dave examine how such a study could have been published despite overwhelming evidence suggesting that such marriages lead to birth defects, and what a sudden influx of Pakistani migrants has to do with it. Plus, in Final Takes, Will and The Crew share their thoughts on last night's tie between the Cowboys & the Packers, before discussing Bad Bunny being selected to headline the Super Bowl halftime show.     Subscribe to ‘Will Cain Country' on YouTube here: ⁠⁠Watch Will Cain Country! ⁠⁠Follow ‘Will Cain Country' on X (@willcainshow), Instagram (@willcainshow), TikTok (@willcainshow), and Facebook (@willcainnews) Follow Will on X: ⁠⁠@WillCain  Learn more about your ad choices. Visit podcastchoices.com/adchoices

At this year's Evidence Based Perioperative Medicine (EBPOM) World Congress we sat down with Ramani Moonesinghe OBE, and had a conversation about her remarkable journey from her immigrant roots to her influential roles in perioperative and critical care. Hear about her contributions to Britain's National Health Service, her groundbreaking research, and her personal life balancing a demanding career with family. Gain insights into the future of perioperative care, health inequalities, and her thoughts on the nation's COVID-19 preparedness. Presented by Andy Cumpstey with Ramani Moonesinghe OBE, Professor of Perioperative Medicine, UCL, and Honorary Consultant in Anaesthesia and Perioperative Medicine, UCLH, London, UK.

Dr. Sarah Myhill has worked full time in National Health Service and independent medical practice. She has a special interest in Chronic Fatigue Syndrome and ME. Show partners: Troscriptions - 10% off your first order by using the code "JESSE" at checkout Quicksilver Scientific - 15% off your first order by using the code "jesse15" at checkout Maui Nui Venison - Get yourself some high quality venison using this link Show notes: https://jessechappus.com/670

In part six of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Krissy Dilger of SRNA was joined by Barbara Babcock, a family therapist from the UK's National Health Service, to discuss the role of siblings in families with a child diagnosed with a rare neuroimmune disorder. Barbara shared findings from her research on how siblings provide crucial support to parents and the positive impacts this has on family dynamics [00:04:31]. They explored the concept of parentification and the importance of assigning age-appropriate tasks to siblings [00:25:10]. Barbara also provided advice on fostering healthy sibling relationships and the significance of open communication [00:35:34]. At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visit https://srna.ngo/submitBarbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk00:00 Introduction00:28 Meet Barbara Babcock02:08 Theme Four: Support from Siblings04:31 Siblings' Characteristics and Their Impact06:57 Voluntary Help from Siblings25:10 Parentification: Understanding the Concept36:34 Fostering Healthy Sibling Relationships39:20 Conclusion and Final Thoughts

Today's headlines include:Victorian Supreme Court Justice Christopher Beale has handed Erin Patterson three life sentences, with the possibility of parole after 33 years. Israel has bombed three high-rise residential buildings in Gaza City, as part of its military takeover of the entire enclave. The eSafety Commissioner has issued a warning to a UK-based tech company that is believed to be “enabling the creation of child sexual exploitation material”. And today’s good news: The UK’s National Health Service has found AI software could significantly increase the recovery rates for people who have had strokes. Hosts: Lucy Tassell and Sam KoslowskiProducer: Elliot Lawry Want to support The Daily Aus? That's so kind! The best way to do that is to click ‘follow’ on Spotify or Apple and to leave us a five-star review. We would be so grateful. The Daily Aus is a media company focused on delivering accessible and digestible news to young people. We are completely independent. Want more from TDA?Subscribe to The Daily Aus newsletterSubscribe to The Daily Aus’ YouTube Channel Have feedback for us?We’re always looking for new ways to improve what we do. If you’ve got feedback, we’re all ears. Tell us here.See omnystudio.com/listener for privacy information.

In this episode, we dive into how artificial intelligence is being developed, tested, and trusted within the UK's National Health Service. Our guest is Adam Byfield, a principal technical assurance specialist with a unique journey from astrophysics to AI assurance. Adam leads a team adapting traditional software testing methods to ensure AI tools in healthcare are safe, effective, and fair,augmenting, not replacing, clinicians. Stay tuned as we unpack the challenges, breakthroughs, and the future of AI in the NHS.

Security professionals have to be integrated into operational resilience efforts and business continuity planning to prevent disruptions of all kinds, according to new research from the ASIS Foundation. In this episode of the SM Highlights podcast, report co-author and ResOrgs principal consultant Joanne Stevenson shares why security gets left out of resilience discussions and what they can do about it. Then, Don Aviv, CPP, PCI, PSP, CEO of Interfor International, discusses what happened during a shooting at a Manhattan office building in July and how proactive threat monitoring can change the nature of site security. Additional Resources Read the ASIS Foundation research, Operational Resilience: The Critical Contribution of Security to Operational Resilience, online here: https://store.asisonline.org/asis-foundation-operational-resilience.html?_gl=1*1l3liqy*_gcl_au*MTE5NTA5MjQzMC4xNzUxMzk3MDA3*_ga*NzQxNzQ1OTA0LjE3NTEzOTcwMDg.*_ga_0ZPVSP549B*czE3NTY4MTYwMjAkbzIwMiRnMSR0MTc1NjgxNjcxNCRqNjAkbDAkaDA ASIS members can access the report for free. Read the free executive summary here: https://www.asisonline.org/globalassets/foundation/research/asis-foundation-operational-resilience-executive-summary.pdf For an overview and analysis of some of the key points of the research, read Security Management's take here: https://www.asisonline.org/security-management-magazine/latest-news/today-in-security/2025/july/Security-Operational-Resilience-Planning/ For more on the cyberattack on the National Health Service in 2017, read the National Audit Office's investigation report: https://www.nao.org.uk/reports/investigation-wannacry-cyber-attack-and-the-nhs/ Interested in using human-centric narratives to back up your metrics? Get some advice and examples here: https://www.asisonline.org/security-management-magazine/articles/2025/03/metrics/crafting-metrics-story/ Interested in how to build out a resilience function, including a crisis response team? Read this article from the SM archive: https://www.asisonline.org/security-management-magazine/articles/2024/07/resilience/create-crisis-managment-team/ Get an overview of the shooting at 345 Park Avenue in Manhattan in Security Management's coverage here: https://www.asisonline.org/security-management-magazine/latest-news/today-in-security/2025/july/345-park-ave-shooting/ Research past security incidents in high-rise buildings here: https://www.asisonline.org/security-management-magazine/articles/2021/03/mitigating-rising-risks-for-high-rises/ Learn more about digital threat monitoring and assessment on social media here: https://www.asisonline.org/security-management-magazine/articles/2025/08/threat-assessment/ Want to explore the changing nature of risk further with Don Aviv, CPP, PCI, PSP, and other security experts? Attend the Game Changer sessions at GSX: https://www.gsx.org/game-changers/

Season 08 Episode 10: Darth Vader and the handshake of deathAlan, Trajce, and Sara start this episode in discussion about the social etiquette of handshakes. Alan advocates for the politeness of the handshake in business negotiations, and Trajce explains his handshake aversions, and the origins of a handshake.In this reverie, Trajce reflects on his support band, warming up big names in the 1980's, like The Village People and Kim Wilde. Sara shares details bout her fun night out listening to Tyne James Organ and Jacob Fitzgerald & the Electric City live at a local venue.On the serious side, Trajce tells a sensation story about a claimant and her award from the Employment Tribunal in the UK, National Health Service. The claimant was awarded money to recover financial loss and punitive costs because of injury, especially to cover her upset feelings, resulting in her mental health disorders. Her grievances included her allegations of the management's poor grievance processes a lack of support through tailored training or engagement, and she was given little control and agency over her work. Sara interprets the concerns in context to psychosocial risk factors. “The kicker,” explains Trajce, and much to Alan's surprise, “is the concern about her colleague labelling her ‘Darth Vader' in a workplace personality typography test.”For more on Psychosocial Risk Management, check out: PRAiSE (Psychosocial Risk Assessment and Integrated Solutions for Employers) – Certified Assessor and Manager programs - and PRA, the new task-based Psychosocial Risk Analyser feature within the ErgoAnalyst software platform. These tools are helping teams visualise, quantify, qualify, and respond to both contextualised physical and psychosocial workplace risks, merging technical rigour with empathy-driven co-design.

As natural thyroid ban looms, thyroid sufferers gird for battle with regulators; Rapid weight loss, muscle wasting—what to do? Could overuse of CT scans cause 100,000 extra cancers in the U.S.? Martha's Vineyard, Nantucket residents afflicted with tick-borne meat allergy; Beyond Meat headed for Chapter 11 bankruptcy; Searching for the causes of low iron.

With all the fun of EdFringe now in full swing, what better way to celebrate the world's biggest arts festival than with another delicious slice of conversation between Thos and Zach Burns, the multitalented perfomer, writer, actor, musician and Fringe veteran! In this fantastic episode, they discuss the eponymously named Fringe! The Musical, the nature of formal musical theatre training, and Zach's latest project, a brand new musical about the birth of the National Health Service called "For All Time".  All this and an exclusive recording of the title song, you'd be potty to miss it.  All together now:  "Tuesday?!"  

At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visit https://srna.ngo/submitIn part five of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Krissy Dilger of SRNA was joined by Barbara Babcock to further explore her research concerning the changing beliefs around parenting when a child has been diagnosed with a rare neuroimmune disorder. They explored the theme of finding a balance in attending to the needs of all children in the family and discussed the importance of fairness and communication between parents [00:02:18]. The conversation also touched on the cultural differences and how these influence family dynamics and parenting strategies when one child requires more attention [00:13:33]. Barbara shared various strategies families use to ensure each child feels valued, such as integrating quality time into existing routines and understanding the different needs of children at various developmental stages [00:18:30]. Barbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk00:00 Introduction 00:28 Meet the Expert: Barbara Babcock02:18 Theme Three: Balancing Sibling Needs03:59 Parental Communication and Mutual Support13:33 Cultural and Family Contexts18:30 Building Quality Time with Siblings26:13 Parental Guilt and Compensation35:09 Conclusion

At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visit https://srna.ngo/submitIn the fourth part of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Krissy Dilger of SRNA continued her conversation with Barbara Babcock. In this episode, Barbara, a family therapist, discussed her research of parental fatigue and limited time distribution among families of children who have been diagnosed with a rare neuroimmune disorder. She elaborated on the non-stop nature of caregiving roles and the impact of work and daily parenting responsibilities on parental exhaustion [00:05:10]. Barbara emphasized the importance of parents finding ways to cope, from getting social support to attending to their own basic needs [00:17:35]. She highlighted the significance of confidence in navigating the complexities of family life and caregiving for a child with special needs [00:21:27].00:00 Introduction01:29 Theme Two: "I Can Only Split Myself So Many Ways"05:10 Parental Exhaustion and Coping Mechanisms17:35 Balancing Social and Extracurricular Activities21:27 Building Confidence as a Family23:28 ConclusionBarbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk

At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visit https://srna.ngo/submitIn the third part of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Krissy Dilger of SRNA was joined by Barbara Babcock to further explore her research concerning the changing beliefs around parenting when a child has been diagnosed with a rare neuroimmune disorder. Barbara discussed how beliefs around being fair as a parent could change and the various sub-themes supporting this idea, including redefinition of fairness and the challenge of balancing attention among children [00:03:30]. She highlighted the impact of societal and historical contexts on parenting norms and the struggles parents face in managing new caregiving responsibilities and learning new skills [00:12:45]. The importance of redefining what it means to be a good parent in the context of a child with additional needs was emphasized throughout the episode [00:24:00]. Barbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk00:00 Introduction 00:27 Meet the Expert: Barbara Babcock01:38 Exploring Parental Beliefs and Fairness03:37 Balancing Attention Among Children07:49 Cultural and Societal Influences on Parenting11:08 Challenges in Managing Illness and Fairness19:37 Learning New Skills and Roles25:52 Redefining Good Parenting27:43 Conclusion

The number of people 85 years and older is expected to double in the U.K. over the next couple of decades. Apian, a London-based health care logistics company that partners with the National Health Service, thinks automation can help. We visit Apian to understand how automated robots could ease the burden of caring for an aging population. Also in this episode: A pilot pushes for menopause policies at British Airways, and an entrepreneur launches a skincare business at 50.Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.

The number of people 85 years and older is expected to double in the U.K. over the next couple of decades. Apian, a London-based health care logistics company that partners with the National Health Service, thinks automation can help. We visit Apian to understand how automated robots could ease the burden of caring for an aging population. Also in this episode: A pilot pushes for menopause policies at British Airways, and an entrepreneur launches a skincare business at 50.Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.

Donald Trump has secured passage of his flagship tax and spending legislation and the US jobs market exceeded expectations last month. Plus, the future of the UK's National Health Service could be in jeopardy, and Hong Kong residents cancel trips to Japan over a comic book's earthquake prophecy. Mentioned in this podcast:What is in Donald Trump's giant tax-cutting billUS economy surpasses expectations to add 147,000 jobs in JuneThe future of the NHS 10-year plan NHSHongkongers scrap Japan trips over comic book's earthquake prophecyToday's FT News Briefing was produced by Sonja Hutson and Katya Kumkova. Additional help from Blake Maples, Michael Lello, and Gavin Kallmann. Our acting co-head of audio is Topher Forhecz. Our intern is Michaela Seah. The show's theme song is by Metaphor Music.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Send us a textSeason 2 Episode 50The Boy's are back in town (no guest this week), Martin gives us a full update on his recent visit to see his Oncologists "Dr P" for an update on his health, Cancer and the results of his most recent Cancer Scan.The results didn't go the way things had been planned and Martin receives the news that a visit to the "Royal Marsdon Hospital" in Chelsea London is required. The Royal Marsden Hospital is a specialist National Health Service oncology hospital in London based at two sites in Brompton, in Kensington and Chelsea, and Belmont in Sutton. It is managed by The Royal Marsden NHS Foundation Trust and supported by The Royal Marsden Cancer Charity.Listen to Martin as he tells us about his news and the next steps in his treatment to carry on the battle of his Stage 4 Cancer.We do finish on a light note today with "Martins Joke of the week"https://www.royalmarsden.nhs.uk#HeartTransplant#eatingdisorder#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#Healthcare#HeartHealth#MedicalBreakthrough#EmotionalJourney#SupportSystem#HealthcareHeroes#PatientStories#CardiologyCare#MedicalJourney#LifeLessons#MentalWellness#HealthAwareness#InspirationalTalk#LivingWithIllness#RareDiseaseAwareness#SharingIsCaring#MedicalSupport#BBCReporter#HeartDisease#PodcastInterview#HealthTalk#Empowerment#Wellbeing#HealthPodcast#Harryhill#Aid's#HIVCheck out our website at www.whostomanddick.com

At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visithttps://srna.ngo/submitIn the second part of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Barbara Babcock shared more about her research on how parents navigate the needs of their non-diagnosed children alongside those of a child with a rare neuroimmune disorder. She described the demographic details of the participating families and the process of recruiting participants for the study [00:02:25]. Barbara highlighted her unique perspective and the potential biases she brought to the research as a non-parent [00:05:33]. She emphasized the importance of honesty and vulnerability in sharing experiences, as well as focusing on the strengths of families facing these challenges [00:09:46]. Barbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk00:00 Introduction01:29 Overview of Barbara's Research02:25 Participant Demographics and Methodology05:33 Researcher's Perspective and Bias09:46 Themes and Insights from the Research12:24 Conclusion

Addressing Fatigue: The Role of Nutrient Deficiencies and Lifestyle Changes. Nutritionist Leyla Muedin details the various causes and potential solutions for fatigue. She highlights how nutrient deficiencies, particularly in vitamins B12, D, and minerals like iron and magnesium, contribute to tiredness. Leyla emphasizes the importance of understanding the root cause of symptoms in integrative and functional medicine. She also touches on lifestyle factors such as stress, sleep patterns, high carbohydrate diets, and alcohol consumption that may exacerbate fatigue. Practical advice on dietary changes and the significance of regular check-ups for vitamin levels is provided, aiming to help listeners address fatigue and improve overall wellness naturally.

Idiopathic intracranial hypertension (IIH), a condition of increased intracranial pressure (ICP), causes debilitating headaches and, in some, visual loss. The visual defects are often in the periphery and not appreciated by the patient until advanced; therefore, monitoring visual function with serial examinations and visual fields is essential. In this episode, Kait Nevel, MD speaks with John J. Chen, MD, PhD, and Susan P. Mollan, MBChB, PhD, FRCOphth, authors of the article “Treatment and Monitoring of Idiopathic Intracranial Hypertension” in the Continuum® June 2025 Disorders of CSF Dynamics issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Chen is a professor of ophthalmology and neurology at the Mayo Clinic in Rochester, Minnesota. Dr. Mollan is an honorary professor of metabolism and systems science in the department of neuro-ophthalmology at University Hospitals Birmingham in Birmingham, United Kingdom. Additional Resources Read the article: Treatment and Monitoring of Idiopathic Intracranial Hypertension Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Guests: @chenmayo, @DrMollan Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kate Nevel. Today, I'm interviewing Drs John Chen and Susan Mollan about their article on treatment and monitoring of idiopathic intracranial hypertension, which appears in the June 2025 Continuum issue on disorders of CSF dynamics. Drs Chen and Mollan, welcome to the podcast. And please, could you introduce yourselves to the audience? Dr Chen: Hello, everyone. I'm John Chen, one of the neuro-ophthalmologists at the Mayo Clinic. Thanks for having us here. Dr Mollan: Yeah, it's great to be with you here. I'm Susan Mollan. I'm a consultant neuro-ophthalmologist in Birmingham, England. Dr Nevel: Wonderful. So great to have you both here today, and our listeners. To start us off, talking about your article, can you share with us what you think is the most important takeaway from your article for the practicing neurologist out there? Dr Chen: Yeah, so our article talked about the treatment and monitoring of IIH. And I think one takeaway point is, IIH is becoming much more prevalent now that there's this worldwide obesity epidemic with obesity having- essentially being the largest risk factor for IIH other than female. It's really important to monitor vision because vision loss is often peripheral vision loss at first, which the patient may be completely unaware of. And so, it's important to pair up with an ophthalmologist so you can monitor the papilledema of the visual fields and make sure they don't get permanent vision loss. And in the article, we also talk about- there's been changes in the treatment of severe IIH, where traditionally, we used VP shunts; but there's been a trend toward using more venous sinus stenting in addition to the traditional surgeries. Dr Nevel: Great, thank you. I think probably most of our listeners or a lot of neurologists out there have a pretty good understanding of kind of the basics of the IIH. But can you kind of just go over a few key characteristics of IIH, and maybe some things that are less commonly known or things that are maybe just been kind of better understood over the past decade, perhaps? Dr Mollan: Yes, certainly. I think, as Dr Chen said, it's because this condition is becoming more prevalent, people recognize it. I think it's- we like to go back to the diagnostic criteria so that we're making a very accurate diagnosis. So, the patients may come in to the emergency room with, say, papilledema that's been identified elsewhere or crashing headaches. And it's important to go through that sort of diagnostic pathway, taking a blood pressure, taking a full blood count to make sure the patient is anemic, and then moving forward with that confirmation of papilledema into urgent neuroimaging, whether it's CT or MRI, but including venography to exclude a venous sinus thrombosis. And then if you have no structural lesion that's causing the raised ICP, it's moving forward with your lumbar puncture and carefully checking those pressures. But the patients may not only have crashing headache, they often have pulsatile tinnitus and neck pain. I think some of the features that we're now recognizing is the systemic metabolic effects that are unique to IIH. And so, there's an increased risk of cardiometabolic disease that's over and above what is conferred by obesity. Also, our patients have a sort of maternal health burden where they get impaired fertility, gestational diabetes and preeclampsia. And there's also an associated mental health burden, amongst other things. So we're really starting to understand the spectrum of the disease a bit more. Dr Nevel: Yeah, thank you for that. And that really struck me in your article, how important it is to be aware of those things so that we're making sure that we're managing our whole patient and connecting them with the appropriate providers for some of those other issues that may be associated. For the practicing neurologist out there without all the neuro-ophthalmology equipment, if you will, what should our bedside exam focus on to help us get maybe an early but accurate picture of the patient's visual function when we suspect IIH to be at play, perhaps before they can get in with the neuro-ophthalmologist? Dr Chen: Yeah, I think at the bedside you can still check visual acuity and confrontational visual fields, you know, with finger counting. Of course, you have to know that those are, kind of, crude kind of ways of screening. With papilledema, oftentimes the visual acuity is intact. And the confrontational visual fields aren't as sensitive as automated perimetry. Another important thing will be to do your direct ophthalmoscope and look at the amount of papilledema. If it's grade one or two papilledema on the more mild side, it's actually not vision threatening. It's the higher degrees of papilledema that can cause rapid vision loss. And so, if you look in and you see grade one papilledema, obviously you need to do the full workup, the MRI, MRV, lumbar puncture. But in terms of rapidly getting to an ophthalmologist to screen for vision loss, it's not going to be as important because you're not going to have vision loss at that low grade. If you look in and you see this rip-roaring papilledema, grade five papilledema, that patient is going to be at very severe risk of vision loss. So, I think that exam, looking at the optic nerve can be very helpful. And of course, talking to the patient about symptoms; is there decreased vision Is there double vision from a sixth nerve palsy? Are there transient visual obscurations which would indicate at least a higher degree of papilledema? That'd be helpful as well. Dr Nevel: Great, thank you. And when the patient does get in with a neuro-ophthalmologist, you talk in your article and, of course, in clinical practice, how OCT testing is important to monitor in this condition. Can you provide for the listeners the definition of OCT and how it plays a role in monitoring patients with IIH? Dr Mollan: Sure. So, OCT is short for optical coherence tomography imaging, and really the eye has been at the forefront of OCT alone. Our sort of cardiology colleagues are catching up on the imaging of blood vessels. But what it allows us to do is give us really good cross-sectional, anatomical-level changes that we can see both in the retina and also at the optic nerve head. And it gives us some really good measurements. It's not so good at sort of saying, is this definitely papilledema or not? That sort of lower end of disc elevation. But it is very good at ruling out what we call the pseudopapilledema. So, things like drusens or these other little masses we find underneath the optic nerve head. But in terms of monitoring, because we can longitudinally take these images and the reproducibility is pretty good at the optic nerve head, it allows us to see whether there's direct changes: either the papilledema getting worse or the papilledema getting better at the optic nerve head. It also gives us some indication of what's going on in the ganglion cell layer complex. And that can be helpful when we're thinking about sort of looking at structure versus function. So, ophthalmologists in general, we love OCT; and we spend much more time nowadays looking at the OCT than we really do the back of the eye. And it's just become critical for patients with papilledema to be able to be very accurate from visit to visit to see what's changing. Dr Nevel: How do you determine how frequently somebody needs to see the neuro-ophthalmologist with IIH and how often they need that OCT evaluation? Dr Chen: Once the diagnosis of IIH is made, how often they need to be seen and how frequent they need to be seen depends on the degree of papilledema. And again, OCT is really nice. You can quantify it and then different providers can actually use the same OCT numbers, which is super helpful. But again, if it's grade three papilledema or higher, or article thickness of 200 or higher, I tend to follow them a little bit more closely, trying to treat them more aggressively. Try to get the papilledema down into a safer zone. If it's grade one or two papilledema, we see them less frequently. So, my first visit might be three months out. They come with grade five papilledema, I'm seeing them within a few days to make sure that's papilledema's come down quickly because we're trying to decide, are they going to need surgery or not? Dr Nevel: Yeah, great. And that's a nice segue into talking a little bit about how we treat patients with IIH after the diagnosis is confirmed. And I'd like to just point out you have a very lovely figure in your article---Figure 5-6,---that I'd like to direct our listeners to read your article and check out that figure, which is kind of an algorithm on how we think about the various treatment options for patients who have IIH, which seems to rely a lot on the degree of presence of papilledema and the presence of vision disturbance. Could you maybe walk us through a little bit about how you think about the different treatment options for patients with IIH and when more urgent surgical intervention might be indicated? Dr Mollan: Yeah, sure. We always find it quite hard in any medical specialty to write these kind of flow diagrams because it's really an individual we're looking at. But these are kind of what we'd say is “broad brushstrokes” into those patients that we worry about, sort of, red disease in those patients, more amber disease. Now obviously, even those patients that may not have severe papilledema, they may have crashing headaches. So, they may be an urgent referral themselves because of that. And so, it's nice to try and work out which end of the spectrum you're working with. If we think of the papilledema, Dr Chen's already laid out the sort of lower end of the prison's scale---our grades one, our grades two---that we're less anxious about. And those patients, we would definitely be having discussions about medical management, which includes acetazolamide therapy; but also thinking about weight management. And it may well be that we talk a little bit further about weight management, but I think it's helpful to sort of coach those conversations after you've made a definite diagnosis. And then laying out the risk that's caused, potentially, the IIH in an individual. And then having a sort of open conversation with them about what changes they can have in their lifestyle alongside thinking about medical therapy. There's some patients with very low levels of papilledema that we decide not to put on medicines initially. As patients progress up that papilledema grade, we're definitely thinking about medical therapy. And our first line from the IIH treatment trial would be using acetazolamide, but we need to be thinking about using appropriate dosing. So, a lot of the patients that I see can be sent to me with very low doses that may be inappropriate for that person. In the IIHTT they used up to four grams daily in a divided dose. And you do need to counsel your patients when you're putting them on acetazolamide because of the side effects. You've got quite a nice table in this article about the side effects. I think if you get the patient on board, that they understand that they will experience side effects, that is helpful because they will expect it, and then possibly tolerate it a bit better. Moving through to that area where we're more anxious, that visual-threatening papilledema. As Dr Chen said, it's sort of like you look in and it's sort of “blood and thunder” in there. And you need to be getting on and encouraging the ophthalmologist to get a formal assessment of the visual field. It's very difficult to determine exactly the level at which- and we talk about the mean deviation in a lot of our research studies. But in general, it's a combination of things: the patient's journey to get to you, their symptoms, what's going on with the visual field, but what's also happening at the OCT. So, we look in and we see that fluid is seeping towards the fovea. We get very anxious, and those patients may not even have enough time for a rapid escalation of acetazolamide. It may well be at the first presentation, which we would term, like, fulminant; that we'd be thinking about surgical intervention. And I think before I stop, the other thing to say is, the surgical landscape is really changing. So, we're having some good studies coming out in terms of stenting. And so, there is a sort of bracket where it may well be that we are thinking about neuroradiological intervention in an earlier case. They may not quite be at that visual-threatening stage, but they may be resistant to medical treatments. Dr Nevel: Thank you for that. What do you think is a potential pitfall or a mistake to avoid, if you will, in the management of patients with IIH? Dr Chen: I think it's- in terms of pitfalls, I think the potential pitfalls I've seen are essentially patients where we don't necessarily create a good patient physician relationship. Where they don't have buy-ins on the treatment, they don't have buy-ins to come back, and they're lost to follow-up. And these patients can be dangerous, because they could have vision threatening papilledema and if not getting the appropriate treatment---and if they're not monitoring the vision---this can lead to poor outcomes. So, I've definitely seen that happen. As Dr Mollan said, you really have to tell them about the side effects from the medications. If you just take acetazolamide, letting them know the paresthesias and the changes in taste and some of these other side effects, they're going to immediately stop the medication. Again, and these medications do work, proven in the IIH treatment trial. So again, I think that patient-physician relationship is very important to make sure they have appropriate follow up. Dr Nevel: The topic of weight loss in this patient population can be tricky, and I know I talked with Susie in a prior interview about how to approach this topic with our patients in a sensitive and compassionate manner. Once this topic is broached, I find many patients are looking for advice on strategies for weight loss, or potentially medications or other interventions. How do you prioritize or think about the different weight loss strategies or treatments with your patients, and how do you think about the way that you recommend these different treatments or not? Dr Mollan: Yeah. I think that's a really great question because we sort of stray here into a specialty that we have not been trained in. One thing I definitely ask my patients: if they've been on a weight loss journey before, and what's worked for them and what's not worked for them. And within our different healthcare systems, we have access to different tiers of weight management approaches. But for the person sitting in front of me, that possibly there may be a long journey to access more professional care, it's about understanding. iIs there things that are free, such as, we have some apps in the National Health Service which are weight management applications where they can actually just start putting in their calories, their daily calorie intake. And those apps can be quite helpful and guiding in terms of targeting areas, but also informing the patient of what types of foods to avoid in their diet and what types of foods to include in their diet. And with some of the programs that are completely complementary, they also sometimes add on things about exercise. But I think it is a really difficult thing to manage as, say, an ophthalmologist or a neurologist, mainly because it's not our area of expertise. And I think we've all got to find, in our local hospitals and healthcare systems, those pathways where the patients may be able to access nutritional support, and sort of behavioral lifestyle therapy support, all the way through to the new medications for weight loss; and also for some people, bariatric surgery pathways. It's a tricky topic. Dr Nevel: So how should we counsel our patients about what to expect in the future in terms of visual outcomes? Dr Chen: I think a lot of that depends on the degree of papilledema when they present. If a patient comes in with grade five papilledema, that fulminant IIH that Dr Mollan had mentioned, these patients can have very severe vision loss. And even if we treat them very aggressively with high-dose medications and urgent surgical interventions, sometimes they can have permanent vision loss. And so, we counsel them that, you know, there's a strong chance that they're going to have a good amount of vision loss. But some patients, we're very surprised and we get a lot of vision back. So, we kind of set expectations, but we're cautiously optimistic that we can get vision back. If a patient presents with more mild papilledema like grade one or two papilledema, they're most likely not going to have any permanent vision loss as long as we're treating them, we're monitoring their vision, they're coming to their follow-ups. They tend to do very well from a vision perspective. Dr Nevel: That's great, thank you. And you know, ties into what you said earlier about really making sure that, you know, we create good- as with any patient, but good physician-patient relationships so that they, you know, trust us and they come to follow up so we can really monitor their vision appropriately. What do you think is going on in research in this area that's exciting? What do you think one of the next breakthroughs or thing that we need to understand the most about treatment and monitoring of IIH? Dr Chen: I think surgically, venous sinus stenting is going to probably take over the bulk of surgeries. We still need that randomized clinical trial, but we have some amazing outcomes with venous sinus stenting. And there's many efforts on randomized clinical trials for venous sinus stenting. So we'll have those results soon. From a medical standpoint, Dr Mollan can actually say, actually, more about this. Dr Mollan: I completely agree. The GLP-1 receptor agonists, the twofold prong approach: one is the weight loss where these patients, you know, have significant weight loss to put their disease into remission; and the other side of it is whether certain GLP-1s have the ability to reduce intracranial pressure. So, a phase 2 study that we undertook here in Birmingham did show that we were able to reduce intracranial pressure, but we don't think it's a class effect. So, I think the sort of big breakthrough will be looking at novel therapies like xenotide and other drugs that, say, work on the proximal kidney tubule. Are they able to reduce intracranial pressure directly? And I think we are on the cusp of a real breakthrough for this disease. Dr Nevel: Great. Thank you so much for chatting with me today. And I really learned a lot, appreciated the opportunity. I hope our listeners learned something today, too. So again, today I've been interviewing Drs John Chen and Susan Mollan about their article on treatment and monitoring of idiopathic intracranial hypertension, which appears in the most recent issue of Continuum on disorders of CSF dynamics. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining us today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

At the end of this mini-series, we will host a Q&A episode where Barbara Babcock will answer questions from the community. To submit your question, please visit:https://srna.ngo/submitIn the first part of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Barbara Babcock discussed the challenges faced by parents raising a child with a rare neuroimmune disorder and the impact on non-diagnosed siblings. Barbara shared her personal journey with transverse myelitis (TM) and how it led her to conduct research on this topic [00:02:20]. She explored themes from her research, highlighting fairness in parenting, and the role of sibling support [00:13:03]. Finally, Barbara emphasized the importance of adapting parenting strategies to balance the needs of all children in the family [00:15:42]. Barbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk00:00 Introduction01:26 Meet Barbara Babcock: A Journey into Family Therapy02:20 Barbara's Personal Experience with TM03:20 Creating Support Systems for Families06:35 Research Focus: Parenting and Sibling Dynamics13:03 Themes from the Research15:42 The Importance of Fairness and Balance18:38 Challenges and Guilt in Parenting24:33 Conclusion

Dr. Sarah Myhill has worked full time in National Health Service and independent medical practice. She has a special interest in Chronic Fatigue Syndrome and ME. Show sponsors: Quicksilver Scientific - 15% off your first order by using the code "ultimatehealth15" at checkout Troscriptions - 10% off your first order by using the code "JESSE" at checkout Show notes: https://jessechappus.com/657

While the global health community wrenches its clothes and gnashes its teeth in Switzerland at the 78th World Health Assembly, Dr Mike Reid, Associate Director of the Center for Global Health Diplomacy, UCSF joins Ben in an entertaining and wide ranging exploration of a positive, forward-looking agenda for global health. Topics include global health security, one health, mis- and disinformation in the doctor-patient relationship, health technology and specific future uses and pitfalls of AI to improve access to healthcare in developing countries.  Mike offers a promise of a future episode on channelling philanthropic dollars into sovereign wealth funds for global health investments. And finally they reflect on their upbringing in the UK with its “free at the point of delivery” National Health Service, and argue over which of the modern Cambridge University Colleges they went to most resembles a multi-story car park.  00:00 Introduction and Overview 00:09 World Health Assembly Insights 01:18 Guest Introduction: Dr. Mike Reed 03:40 Mike Reid's  Background and Career 05:58 Global Health Security and Solidarity 11:28 The One Health Agenda 14:12 Artificial Intelligence in Global Health 37:26 Navigating Healthcare Systems 43:48 Closing Remarks and Future Topics Mike's Substack:  https://reimaginingglobalhealth.substack.com/

It's Friday, May 16th, A.D. 2025. This is The Worldview in 5 Minutes heard on 125 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Adam McManus Nigerian Muslims kill 2 Christian teachers Boko Haram Muslim terrorists recently targeted Christians traveling near a Nigerian army base along the deadly Damboa–Maiduguri highway, reports International Christian Concern. On May 12th, two Christian teachers were killed and several others were injured when their vehicle struck an improvised explosive device allegedly planted by the Islamic terror group. Blessing Luka and Gideon Bitterleaf were both devoted Christian educators with the Damboa Local Education Authority. Pray that these Muslim murderers will be held accountable. Genesis 9:6 says, "Whoever sheds human blood, by humans shall their blood be shed; for in the image of God has God made mankind." More children in United Kingdom have gender dysphoria Soaring numbers of children in England and Wales are waiting for specialist gender care from the National Health Service -- as youngsters of any age are now eligible for referral after the health service “caved to the pressure” of transgender activists to remove age limits, reports The Daily Mail and World Magazine. Average waiting times have grown to more than two years for a confused child to get a first appointment at a specialist health service clinic, with 157 of those aged under ten. There were 6,225 confused kids on the national waiting list at the end of March. That's up 12 per cent from the same point a year earlier. Young children believed to have gender dysphoria are generally given counselling and therapy with their family, but thankfully no longer prescribed hormone treatments.  Indeed, Britain's National Health Service has moved away from a “medical model” in favor of a “holistic” approach to children's gender care, as per recommendations from the Cass Review. Puberty blockers are no longer prescribed to children for the treatment of gender dysphoria, after a ban last year was made permanent in December. Former FBI Director calls for Trump's assassination Former FBI Director James Comey is facing massive backlash after he posted a photo on his Instagram page calling for the assassination of President Donald Trump, reports Christian Talk show host Todd Starnes. An image of seashells that had been arranged on the beach to spell “86 47” was posted on Comey's personal Instagram account. The number “86” is code for killing someone. And, of course, “47” refers to the fact that Donald Trump is the 47th president of the United States. Comey wrote, “Cool shell formation on my beach walk.” Homeland Security Secretary Kristi Noem tweeted, “Disgraced former FBI Director James Comey just called for the assassination of President Trump. [the Department of Homeland Security] and Secret Service is investigating this threat and will respond appropriately.” And Republican Senator Tommy Tuberville of Alabama tweeted, “This is a direct THREAT against President Trump, who has already survived two assassination attempts. BEYOND despicable. James Comey MUST face consequences.” RFK Jr. agrees to examine the dangers of Abortion Kill Pill A recent study by the Ethics and Public Policy Center on the Abortion Kill Pill, mifepristone, showed that 11% of women experience adverse effects serious enough to send them to the Emergency Room. That's 22 times higher than what the Food and Drug Administration claims.   Appearing before the Senate Health, Education, Labor, and Pensions Committee on May 15th, Health and Human Services Secretary Robert F. Kennedy Jr. agreed to a comprehensive review and relabeling of Mifepristone in response to a pointed question from Republican Senator Josh Hawley of Missouri, reports The Guardian. Listen. HAWLEY: “There's been a major study by the Ethics and Public Policy Center of 865,727 prescribed cases of mifepristone abortions, chemical abortions, between 2017 and 2023. This data shows the biggest study on mifepristone done, I think, ever, and it showed that nearly 11% of women experience very serious adverse health effects to include sepsis, hemorrhaging, infection, of course, emergency room visits. That rate is 22 times higher than the FDA's current label which says it's just 0.5 the incidence of serious adverse health events. “So, my question to you is this: You previously testified at the committee that you would do a top-to-bottom review of mifepristone. Do you continue to stand by that? And don't you think that this new data shows the need to do a review is, in fact, very pressing?” KENNEDY: “It's alarming, and clearly it indicates that, at very least, the label should be changed. I've asked Marty Makary, who's the director of FDA, to do a complete review and to report back.” HAWLEY: “Good!” South Carolina Supreme Court affirms Heartbeat Law The South Carolina Supreme Court ruled that the state may enforce its heartbeat-based abortion ban, rejecting an argument by Planned Parenthood to weaken the law, reports LifeSiteNews.com. Enacted in 2023, the law effectively bans most abortions after about six weeks gestation. South Carolina Republican Governor Henry McMaster told the Daily Wire, “Time and time again, we have defended the right to life in South Carolina, and time and time again, we have prevailed. Today's ruling is another clear and decisive victory that will ensure the lives of countless unborn children remain protected and that South Carolina continues to lead the charge in defending the sanctity of life.” Psalm 127:3 says, "Children are a heritage from the Lord, the fruit of the womb a reward." Christian band under fire by atheists and superintendent And finally, a popular Christian band is under fire from atheists along with Davidson County Schools in North Carolina, reports Blue Ridge Broadcasting. The 3 Heath Brothers band had been invited to host an anti-bullying event at Hasty Elementary School. Their performance included a number of songs that mentioned God. Afterwards, they gave the kids a devotional pamphlet that included Bible verses. The Freedom From Religion Foundation was enraged over the performance and accused the school of being a recruiting ground for Christianity. The God-hating attorney, Madeline Ziegler, wrote, “The district cannot allow non-school persons to treat schools as a recruiting ground for their religious mission.  Public schools are not an appropriate place for outside adults to convince students to convert to Christianity.” Sadly, the School Superintendent Gregg Slate was just as horrified with the Christian band and wrote a lengthy letter of apology to the atheists. But then, the school district went a step further. They had the audacity to demand that the 3 Heath Brothers remove video of the event from their social media pages. A bizarre request indeed. School officials claim they were duped. But Nicholas Heath of the 3 Heath Brothers denied that there was any proselytizing or worship service at the event. Close And that's The Worldview on this Friday, May 16th, in the year of our Lord 2025. Subscribe for free by Spotify, Amazon Music or by iTunes or email to our unique Christian newscast at www.TheWorldview.com. Or get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Dr. Nadeem Haddadin-Crowe discusses witch hunts in the National Health Service prompted by politicians and Israel lobby groups.

"We are aiming for a place where we can decouple the scorecard from our worthiness. It's of course the case that in trying to optimise the good, we will always be falling short. The question is how much, and in what ways are we not there yet? And if we then extrapolate that to how much and in what ways am I not enough, that's where we run into trouble." —Hannah BoettcherWhat happens when your desire to do good starts to undermine your own wellbeing?Over the years, we've heard from therapists, charity directors, researchers, psychologists, and career advisors — all wrestling with how to do good without falling apart. Today's episode brings together insights from 16 past guests on the emotional and psychological costs of pursuing a high-impact career to improve the world — and how to best navigate the all-too-common guilt, burnout, perfectionism, and imposter syndrome along the way.Check out the full transcript and links to learn more: https://80k.info/mhIf you're dealing with your own mental health concerns, here are some resources that might help:If you're feeling at risk, try this for the the UK: How to get help in a crisis, and this for the US: National Suicide Prevention Lifeline.The UK's National Health Service publishes useful, evidence-based advice on treatments for most conditions.Mental Health Navigator is a service that simplifies finding and accessing mental health information and resources all over the world — built specifically for the effective altruism communityWe recommend this summary of treatments for depression, this summary of treatments for anxiety, and Mind Ease, an app created by Spencer Greenberg.We'd also recommend It's Not Always Depression by Hilary Hendel.Some on our team have found Overcoming Perfectionism and Overcoming Low Self-Esteem very helpful.And there's even more resources listed on these episode pages: Having a successful career with depression, anxiety, and imposter syndrome, Hannah Boettcher on the mental health challenges that come with trying to have a big impact, Tim LeBon on how altruistic perfectionism is self-defeating.Chapters:Cold open (00:00:00)Luisa's intro (00:01:32)80,000 Hours' former CEO Howie on what his anxiety and self-doubt feels like (00:03:47)Evolutionary psychiatrist Randy Nesse on what emotions are for (00:07:35)Therapist Hannah Boettcher on how striving for impact can affect our self-worth (00:13:45)Luisa Rodriguez on grieving the gap between who you are and who you wish you were (00:16:57)Charity director Cameron Meyer Shorb on managing work-related guilt and shame (00:24:01)Therapist Tim LeBon on aiming for excellence rather than perfection (00:29:18)Author Cal Newport on making time to be alone with our thoughts (00:36:03)80,000 Hours career advisors Michelle Hutchinson and Habiba Islam on prioritising mental health over career impact (00:40:28)Charity founder Sarah Eustis-Guthrie on the ups and downs of founding an organisation (00:45:52)Our World in Data researcher Hannah Ritchie on feeling like an imposter as a generalist (00:51:28)Moral philosopher Will MacAskill on being proactive about mental health and preventing burnout (01:00:46)Grantmaker Ajeya Cotra on the psychological toll of big open-ended research questions (01:11:00)Researcher and grantmaker Christian Ruhl on how having a stutter affects him personally and professionally (01:19:30)Mercy For Animals' CEO Leah Garcés on insisting on self-care when doing difficult work (01:32:39)80,000 Hours' former CEO Howie on balancing a job and mental illness (01:37:12)Therapist Hannah Boettcher on how self-compassion isn't self-indulgence (01:40:39)Journalist Kelsey Piper on communicating about mental health in ways that resonate (01:43:32)Luisa's outro (01:46:10)Audio engineering: Ben Cordell, Milo McGuire, Simon Monsour, and Dominic ArmstrongContent editing: Katy Moore and Milo McGuireTranscriptions and web: Katy Moore

#574: What would you do if someone in authority told you to do something that felt wrong? Most of us like to think we'd speak up, push back, stand our ground. But research tells a very different story. In fact, when Yale researchers conducted a famous experiment in the 1960s, they found that 65% of people would administer what they believed to be deadly electric shocks to another human being... simply because someone in a lab coat told them to. Today's guest has spent over 15 years studying why humans comply with authority - even when every fiber of our being is screaming that we shouldn't. And when it comes to our money, this tendency to comply with authority figures - from financial advisors to real estate agents to car salespeople - can cost us dearly. Dr. Sunita Sah began her career as a physician in the UK's National Health Service. During one particularly exhausting period as a junior doctor, she agreed to meet with a financial advisor who had contacted her at work. That meeting sparked questions that would shape the rest of her career: Why did she feel pressured to trust this advisor, even after learning he had a conflict of interest? Today, she's a tenured professor at Cornell University, where her groundbreaking research on compliance and influence has been featured in The New York Times and Scientific American. She's advised government agencies, served on the National Commission on Forensic Science, and helps leaders understand the psychology behind why we say "yes" when we really want to say "no." Whether you're meeting with a financial advisor, negotiating the price of a home, or discussing rates with a contractor, understanding the psychology of compliance could save you thousands of dollars - and help you make better financial decisions. Today's conversation isn't just about psychology - it's about protecting your wealth by learning when and how to say "no." Resources Mentioned in the Episode: - Website: sunitasah.com - Newsletter: Defiant by Design on Substack - Connect with Dr. Sah on LinkedIn - Follow Dr. Sah on Instagram About Dr. Sunita Sah Dr. Sunita Sah is a tenured professor at Cornell University specializing in organizational psychology. Her research focuses on how and why people comply with authority, even against their better judgment. A former physician in the UK's National Health Service, Dr. Sah brings a unique perspective to understanding human behavior and decision-making. Her work has been featured in leading publications including The New York Times and Scientific American, and she has served as a Commissioner on the National Commission on Forensic Science. Timestamps: Note: Timestamps will vary on individual listening devices based on dynamic advertising run times. The provided timestamps are approximate and may be several minutes off due to changing ad lengths. 0:00 Intro 4:00 Most people follow authority against their own judgment 7:01 Dr. Sah meets a pushy financial advisor as a young doctor 9:55 Why conflict-of-interest disclosures backfire 12:16 "Insinuation anxiety" makes us cave under pressure 14:13 The "sales pitch effect" creates unwanted obligation 17:29 Growing up conditioned to comply as a South Asian daughter 20:34 Career paths: following passion vs family expectations 27:29 The Milgram experiments reveal our tendency to obey 35:28 Using "quiet defiance" to resist pressure 42:20 Why managers misunderstand employee silence 46:43 Five elements that separate consent from compliance 53:03 Building defiance through small daily practices 58:13 The power of the pause in decision-making 1:02:54 Five stages to recognize and act on resistance 1:18:22 How to develop your personal style of defiance For more information, visit the show notes at https://affordanything.com/episode574 Learn more about your ad choices. Visit podcastchoices.com/adchoices